TriangleCyclophosphamide (NCT07224100)
Cyclophosphamide trial for B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 (NCT07224100). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with newly diagnosed Philadelphia-positive B-cell acute lymphoblastic leukemia, with abnormal lymphoblasts in blood or bone marrow.
The idea: ponatinib blocks BCR::ABL1 signaling. Daily oral ponatinib is combined with dose-adjusted EPOCH chemotherapy, which attacks cell growth and DNA. Only CD20-positive disease receives rituximab. Cycles repeat every three weeks, for up to eight cycles. Researchers measure complete molecular response after four cycles, using a sensitive BCR::ABL1 test. Blood and marrow samples are collected.
This phase 2 study plans 33 patients. Ryan Cassaday leads in Seattle, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.